Dr. Jeffrey R. Jay, M.D.
Latest statistics and disclosures from Great Point Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NGNE, ABVX, PLRX, EOLS, VRDN, and represent 36.52% of Great Point Partners's stock portfolio.
- Added to shares of these 8 stocks: Oruka Therapeutics (+$13M), VRDN (+$5.7M), UNCY, PMN, RNAC, OLMA, ELYM, TCRX.
- Started 5 new stock positions in PMN, Oruka Therapeutics, ELYM, UNCY, RNAC.
- Reduced shares in these 10 stocks: URGN (-$27M), ACLX (-$24M), EOLS (-$21M), INSM (-$17M), , MRUS (-$14M), DNTH (-$13M), ESPR (-$13M), DVAX (-$12M), CYTK (-$8.4M).
- Sold out of its positions in SYRE, FOLD, ANAB, ESPR, INSM, KYTX, LXRX, PBYI, TERN.
- Great Point Partners was a net seller of stock by $-186M.
- Great Point Partners has $340M in assets under management (AUM), dropping by -34.91%.
- Central Index Key (CIK): 0001281446
Tip: Access up to 7 years of quarterly data
Positions held by Dr. Jeffrey R. Jay, M.D. consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Great Point Partners
Great Point Partners holds 29 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Neurogene (NGNE) | 12.4 | $42M | 1.0M | 41.96 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 7.2 | $25M | -13% | 2.1M | 11.52 |
|
| Pliant Therapeutics (PLRX) | 6.3 | $21M | -27% | 1.9M | 11.21 |
|
| Evolus (EOLS) | 5.6 | $19M | -52% | 1.2M | 16.20 |
|
| Miragen Therapeutics (VRDN) | 5.0 | $17M | +50% | 750k | 22.75 |
|
| Arcellx Common Stock (ACLX) | 4.9 | $17M | -59% | 200k | 83.51 |
|
| Cytokinetics Com New (CYTK) | 4.9 | $17M | -33% | 316k | 52.80 |
|
| Kalvista Pharmaceuticals (KALV) | 4.4 | $15M | -2% | 1.3M | 11.58 |
|
| Dynavax Technologies Corp Com New (DVAX) | 4.3 | $15M | -44% | 1.3M | 11.14 |
|
| Context Therapeutics (CNTX) | 4.0 | $14M | -6% | 6.9M | 1.96 |
|
| Zura Bio Class A Ord Shs (ZURA) | 3.9 | $13M | -29% | 3.3M | 4.06 |
|
| Oruka Therapeutics | 3.7 | $13M | NEW | 515k | 24.51 |
|
| Merus N V (MRUS) | 3.7 | $13M | -52% | 250k | 49.96 |
|
| Olema Pharmaceuticals (OLMA) | 3.5 | $12M | +25% | 1.0M | 11.94 |
|
| Ionis Pharmaceuticals (IONS) | 3.0 | $10M | -22% | 255k | 40.06 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 3.0 | $10M | -18% | 2.8M | 3.63 |
|
| Urogen Pharma (URGN) | 2.8 | $9.6M | -73% | 759k | 12.70 |
|
| Optinose (OPTN) | 2.5 | $8.6M | -6% | 13M | 0.67 |
|
| Dianthus Therapeutics (DNTH) | 2.2 | $7.5M | -63% | 275k | 27.38 |
|
| Outlook Therapeutics (OTLK) | 2.0 | $6.9M | -24% | 1.3M | 5.34 |
|
| Jasper Therapeutics Com New (JSPR) | 1.8 | $6.1M | -19% | 322k | 18.81 |
|
| Voyager Therapeutics (VYGR) | 1.7 | $5.6M | -40% | 960k | 5.85 |
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.5 | $5.2M | 500k | 10.45 |
|
|
| Tscan Therapeutics (TCRX) | 1.5 | $5.1M | +8% | 1.0M | 4.98 |
|
| Unicycive Therapeutics (UNCY) | 1.0 | $3.5M | NEW | 8.6M | 0.41 |
|
| Promis Neurosciences Com New (PMN) | 1.0 | $3.5M | NEW | 2.8M | 1.25 |
|
| Cartesian Therapeutics Com New (RNAC) | 0.9 | $3.2M | NEW | 200k | 16.12 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.6 | $2.0M | -55% | 674k | 3.01 |
|
| Eliem Therapeutics (ELYM) | 0.4 | $1.3M | NEW | 248k | 5.09 |
|
Past Filings by Great Point Partners
SEC 13F filings are viewable for Great Point Partners going back to 2013
- Great Point Partners 2024 Q3 filed Nov. 13, 2024
- Great Point Partners 2024 Q2 filed Aug. 14, 2024
- Great Point Partners 2024 Q1 filed May 15, 2024
- Great Point Partners 2023 Q4 filed Feb. 14, 2024
- Great Point Partners 2023 Q3 filed Nov. 14, 2023
- Great Point Partners 2023 Q2 filed Aug. 14, 2023
- Great Point Partners 2023 Q1 filed May 15, 2023
- Great Point Partners 2022 Q4 filed Feb. 14, 2023
- Great Point Partners 2022 Q3 filed Nov. 14, 2022
- Great Point Partners 2022 Q2 filed Aug. 15, 2022
- Great Point Partners 2022 Q1 filed May 16, 2022
- Great Point Partners 2021 Q4 filed Feb. 14, 2022
- Great Point Partners 2021 Q3 filed Nov. 15, 2021
- Great Point Partners 2021 Q2 filed Aug. 16, 2021
- Great Point Partners 2021 Q1 filed May 17, 2021
- Great Point Partners 2020 Q4 filed Feb. 16, 2021